Request Demo

Last update 08 Oct 2025

Trazodone Hydrochloride

Last update 08 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryTrazodone, a small molecule drug, targets the serotonin transporter and acts as a serotonin reuptake inhibitor. Although approved for treating several conditions, including major depressive disorder, diabetic neuropathies, sleep initiation and maintenance disorders, and premature ejaculation, the drug's mechanism of action remains elusive. Angelini Pharma was the first to approve the drug for use in December 1981. By increasing serotonin levels in the brain, Trazodone hydrochloride reduces symptoms of depression and improves mood. Additionally, the drug has sedative properties that make it effective in treating sleep disorders. However, Trazodone may produce unwanted side effects such as dizziness, drowsiness, and dry mouth and interact with other medications, resulting in unwanted consequences.

Drug Type

Small molecule drug

Synonyms

Oleptro, Trazodone, Trazodone HCl

+ [17]

Target

5-HT2 receptor x SERT

Action

antagonists

Mechanism

5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), Serotonin reuptake inhibitors

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases+ [1]

Active Indication

Depressive Disorder, MajorDepressive DisorderDiabetic peripheral neuropathy+ [2]

Inactive Indication

Anxiety DisordersDiabetic peripheral neuropathic pain

Originator Organization

Angelini Pharma, Inc.

Active Organization

Angelini Pharma, Inc.

Organon & Co.

Pfizer Japan, Inc.

+ [5]

Inactive Organization

Lee's Pharmaceutical Holdings Ltd.

Zhaoke Pharmaceutical (Hefei) Co., Ltd.

Pragma Pharmaceuticals LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 1981),

Depressive Disorder, Major

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC19H23Cl2N5O

InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N

CAS Registry25332-39-2

139

Clinical Trials associated with Trazodone Hydrochloride

NCT07210606

/ Not yet recruitingPhase 4IIT

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

Start Date01 Jan 2026

Sponsor / Collaborator

VA Office of Research and Development

NCT07136415

/ Not yet recruitingPhase 4IIT

CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People

The goal of this clinical trial is to learn how three current insomnia therapies (trazodone, daridorexant, cognitive behavioral therapy for insomnia) compare with each other in peri- and post-menopausal women. It will also learn about the safety of the treatments. The main questions it aims to answer are:
Which commonly used insomnia therapies are most effective and safe for improving insomnia symptoms in peri- and post-menopausal people?
How well do the therapies work for people from different socio-demographic backgrounds, who are at different stages of menopause, and who have different menopause-associated conditions (e.g., sleep apnea, mood disturbance, etc.)?
What medical problems do participants have when taking part in these treatments?
Participants will:
Be asked to take trazodone every night, take daridorexant every night, or participate in a behavioral program for insomnia, for a duration of 12 months.
Participate in a total of one in-person visit and 5 virtual visits (phone calls) over the 12 months.
Wear (and keep) a Fitbit and fill out a daily sleep diary for at least 4 weeks over the 12 months.
Fill out online surveys at 5 time-points over the 12 months.

Start Date01 Dec 2025

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

[+6]

NCT07210112

/ Not yet recruitingPhase 2IIT

Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
The benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed. Moreover, the role of 5-HT2A receptors, involved in the psychedelic experience, on the therapeutic efficacy of psilocybin is still poorly understood. For example, pre-administration of trazodone, a 5-HT2A antagonist antidepressant, could annihilate the acute subjective effects of psilocybin without altering its beneficial effects (Rosenblat et al., 2023). We intend to test this hypothesis by comparing, in a randomized, double-blind, placebo-controlled study, the effect of two possible doses of trazodone (total or partial occupancy of 5-HT2A receptors) on the benefit/risk ratio of psilocybin.
We hypothesize that the therapeutic effects of psilocybin are partially independent of 5-HT2A receptor activation and thus persist even after total or partial neutralization of its acute subjective effects.

Start Date08 Oct 2025

Sponsor / Collaborator

Centre Hospitalier Saint-Anne

100 Clinical Results associated with Trazodone Hydrochloride

100 Translational Medicine associated with Trazodone Hydrochloride

100 Patents (Medical) associated with Trazodone Hydrochloride

3,615

Literatures (Medical) associated with Trazodone Hydrochloride

01 Nov 2025·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features

Article

Author: Cuomo, Alessandro ; Mariantoni, Elisa ; Carmellini, Pietro ; Pinzi, Mario ; Pierini, Caterina ; Fagiolini, Andrea ; Pardossi, Simone

Psychomotor agitation is a challenging symptom of major depressive disorder with mixed features (MDD-MF), often worsening outcomes and complicating treatment. This retrospective study assessed the efficacy and tolerability of intravenous trazodone in 97 hospitalized patients with MDE-MF. Symptom severity was evaluated using montgomery asberg depression rating Scale (MADRS), young mania rating scale, hamilton anxiety rating scale, GAD-7, and clinical global impression scale-severity of illness (CGI-S) scales, with significant reductions in agitation, anxiety, and irritability observed early during treatment. Correlation analyses revealed significant negative associations between intravenous (IV) trazodone dosage and improvements in MADRS (r = −0.23; P < 0.05), item 5 of GAD-7 (r = −0.27; P < 0.001), and CGI-S scores (r = −0.22; P < 0.05). Therapy duration also correlated negatively with improvements in GAD-7 item 5 (r = −0.29; P < 0.001) and CGI-S (r = −0.27; P < 0.001), indicating diminishing returns with prolonged treatment. Regression analyses showed that therapy duration, but not dosage, significantly influenced improvements in GAD-7 item 5 and CGI-S. Trazodone was well-tolerated, with only mild side effects in 11.3% of patients. These findings suggest that IV trazodone effectively reduces agitation and related symptoms in MDD-MF, particularly in the early treatment phase, emphasizing the importance of optimizing treatment duration. Future studies should investigate individualized dosing strategies and explore long-term outcomes in this population.

01 Nov 2025·INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Managing depression in the elderly: real-world clinical considerations and perspectives

Article

Author: Incalzi, Raffaele Antonelli ; Kasper, Siegfried ; Bozzali, Marco ; Siwek, Marcin ; Morgado, Pedro

This study aims to elucidate current trends in clinical practice for managing depression in elderly patients, focusing on the utilization of pharmacotherapeutics and integrated care models to improve patient outcomes. A comprehensive survey was conducted among physicians from various European countries to gather insights into prescribing habits, treatment patterns, and the impact of comorbidities on therapeutic choices, with a focus on trazodone. The participants included psychiatrists, general practitioners, and neurologists actively involved in elderly depression care. The findings reveal a preference among physicians for using antidepressants like trazodone, due to efficacy and tolerability. Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors were also commonly prescribed, while tricyclic antidepressants and monoamine oxidase inhibitors were less favored. Psychiatric conditions and sleep disturbances significantly influenced treatment decisions. The survey underscored the importance of multidisciplinary management and the crucial role of caregivers in the treatment process. Effective management of depression in the elderly demands a precision approach that incorporates a thorough understanding of pharmacology, comorbidities, and a collaborative approach to maximize the effects of treatment while trying to minimize polypharmacy and the co-occurring side effects. The study highlights the need for tailored treatment strategies that address the complex needs of the elderly to enhance their quality of life and treatment outcomes.

01 Oct 2025·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The effects of trazodone exposure during pregnancy on fetal outcomes: a systematic review

Review

Author: Garcia-Bournissen, Facundo ; Glasgow-Osment, Britney ; Wahib, Farah ; Zanin, Madeleine ; Kassam, Shama

PURPOSE:

Trazodone, a medication primarily used for anxiety and insomnia, is increasingly prescribed during pregnancy despite limited safety data. This systematic review aims to assess the effects of trazodone exposure during pregnancy on fetal outcomes.

METHODS:

A search was conducted using MEDLINE and Embase databases from the year 2000 to present. Studies were limited to those involving human subjects, published in English, and investigating trazodone exposure during pregnancy. Keywords included "pregnan*," "trazodone," "malformation*," and "birth outcomes." Four reviewers independently extracted data from the selected records. Risk of bias was assessed using the Newcastle-Ottawa Scale. Data synthesis involved a qualitative analysis to summarize and interpret the findings, identifying patterns across the studies.

RESULTS:

Fourteen studies met the inclusion criteria. The main outcome measures included fetal and pregnancy outcomes such as congenital malformations, developmental outcomes, poor neonatal adaptation syndrome (PNAS), persistent pulmonary hypertension of the newborn (PPHN), congenital heart defects, gestational age, birth weight, stillbirth, preterm birth, spontaneous and therapeutic abortion, and pre-eclampsia.

CONCLUSION:

The review found no consistent evidence linking trazodone use during pregnancy to increased risks of congenital malformations, stillbirths, or low birth weight. However, some studies suggested a possible association with an increased risk of spontaneous and therapeutic abortions. Given the limited and varied data, further research with larger, well-controlled studies are needed to establish the safety profile of trazodone during pregnancy. Overall, clarifying the specific risks and benefits of trazodone use in pregnancy will better guide clinical decision-making and improve maternal-fetal health outcomes.

TRIAL REGISTRATION:

PROSPERO number: CRD42024503611.

News (Medical) associated with Trazodone Hydrochloride

15 Sep 2025

·www.einpresswire.com

Sleep Script MD Offers Affordable $25 Entry Plan for Personalized Insomnia Care

A leading telehealth option for better sleep, combining medical expertise with affordable care and non-addictive treatments, starting at only $25. SHELBYVILLE, TN, UNITED STATES, September 15, 2025 / EINPresswire.com / -- SleepScriptMD , a leading professional telehealth platform and subsidiary of RefillGenie Inc., offers comprehensive insomnia treatment through its affordable $25 entry plan, providing patients nationwide with access to physician-supervised sleep care without traditional clinic visits. The platform addresses the growing need for accessible sleep healthcare by combining medical expertise with modern telehealth technology. With sleep disorders affecting millions of Americans, SleepScriptMD provides an alternative to conventional sleep clinics through its dual-care system that accommodates different patient preferences and state regulations. Comprehensive Sleep Care Through Telemedicine • Physician oversight: Board-certified doctors review every treatment plan, ensuring safe, evidence-based care. • Non-addictive medications: The platform exclusively prescribes non-habit-forming sleep medications, avoiding controlled substances. • Flexible care options: Asynchronous care is available in most states, with virtual appointments required by local telehealth laws. • Same-day prescriptions: Treatment plans are typically processed within hours of intake completion. • Transparent pricing: $25 first month, $42 monthly thereafter, with 90-day options available. The service operates in over 40 states, with asynchronous care available in most locations. States requiring virtual appointments include Connecticut, Georgia, Indiana, Kansas, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Ohio, Tennessee, Texas, and West Virginia. "We saw a critical need for effective, affordable solutions to improve sleep health—solutions that are safe, non-addictive, and delivered with expertise," said Dr. David Danish, spokesperson for SleepScriptMD. "Our platform bridges the gap between traditional sleep medicine and modern convenience." SleepScriptMD's three-tiered medication system focuses on non-controlled prescription options, including Trazodone for improving slow wave sleep, Clonidine for calming the nervous system, and Vistaril (hydroxyzine) for its calming antihistamine properties. The platform excludes benzodiazepines and Z-drugs from its formulary to prevent dependency risks. Patient Matthew shared his experience: "The process was simple, and I liked that they actually explained my options instead of just pushing whatever. It took a couple of tweaks to get the right prescription, but now I'm finally sleeping through the night. Totally worth it." The platform's design addresses common barriers to sleep healthcare, including appointment scheduling difficulties, geographic limitations, and cost concerns. Patients complete secure online intakes at their convenience, with no insurance requirements for service access. Priya, another patient, noted: "I've been dealing with bad sleep for years, and nothing really helped. This was the first time I actually felt like I was being listened to. The process was quick, and the meds they prescribed have made a huge difference." Co-founded by Dr. Peter Kelly, a family medicine specialist, and Dr. David Danish, dual board certified in child/adolescent and adult psychiatry, SleepScriptMD combines complementary medical backgrounds to ensure comprehensive patient care. Their collaboration began during post-baccalaureate studies at a prestigious premedical program affiliated with Harvard. The platform offers both AI-assisted asynchronous care and virtual telehealth options, enabling patients to choose their preferred care method based on individual needs and state requirements. Patient Jamal E. described his virtual session experience: "My sleep was trash, and nothing was helping. I did the virtual session so I could actually talk to a doctor, and they knew their stuff. They explained why some meds are better than others for my situation, which made a lot of sense. It's been a huge difference for me. 10/10 recommend." Beyond prescription medications, SleepScriptMD provides natural supplement recommendations and at-home sleep testing options for patients who may have underlying sleep apnea. The platform maintains commitment-free service with no hidden fees and cancellation flexibility. The service includes ongoing support for dose adjustments and medication changes, ensuring patients receive personalized care throughout their treatment journey. For more information about SleepScriptMD's sleep care services, visit https://sleepscriptmd.com or call +1 800-737-8385. Additional mental health insights are available at https://sleepscriptmd.com/expert-mental-health-insights/ . ### About SleepScriptMD SleepScriptMD, a subsidiary of RefillGenie Inc., and headquartered in Shelbyville, Tennessee, provides accessible, high-quality sleep healthcare through telemedicine. Co-founded by Dr. Peter Kelly (family medicine) and Dr. David Danish (dual board certified in child/adolescent and adult psychiatry), the platform combines complementary medical expertise to deliver comprehensive sleep care. The service offers both AI-assisted asynchronous care and virtual telehealth options, enabling patients to access personalized sleep solutions with safety and efficiency while maintaining the highest standards of medical oversight. Contact Details: 118 East Side Square Ste. A Shelbyville, TN 37160 United States Notes to Editors: • All clinical care is delivered by licensed physicians or nurse practitioners in accordance with state telehealth laws. • The medications discussed (Trazodone, Clonidine, Hydroxyzine) are non-controlled and selected through an evidence-based, physician-guided system. • For asynchronous eligibility, state-specific regulations apply. End of Press Release. Dr. David Danish SleepScriptMD +1 800-737-8385 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

13 Aug 2025

·www.einpresswire.com

SleepScript MD Offers Nationwide Telemedicine Program for Prescription Sleep Medication Access

Physician-led telehealth sleep clinic provides fast care using safe, non-addictive medications across 40+ states. SHELBYVILLE, TN, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Sleep disorders affect millions of working professionals across the United States, creating a significant healthcare challenge that traditional medical systems struggle to address efficiently. SleepScript MD , a subsidiary of RefillGenie Inc. , provides a nationwide telemedicine program specifically designed to address prescription sleep medication access for busy professionals suffering from sleep disorders. The physician-led insomnia clinic delivers safe, research-backed sleep treatment through asynchronous care in most states, eliminating the need for appointments or office visits. Licensed physicians and nurse practitioners personally review each case to ensure appropriate care without relying on automated systems. Traditional sleep medicine often requires multiple appointments, extended wait times, and rigid scheduling that conflicts with demanding professional schedules. The platform addresses these barriers by offering: • Same-day prescription processing in most states • No appointment requirements for eligible patients in approved states • Comprehensive online intake assessments available 24/7 • Direct prescription delivery to preferred pharmacies "We saw a critical need for effective, affordable solutions to improve sleep health—solutions that are safe, non-addictive, and delivered with expertise," stated Dr. David Danish, spokesperson for SleepScript MD. The service exclusively prescribes non-habit-forming medications, specifically avoiding controlled substances. The platform employs a three-tiered medication system including: • Trazodone for improved slow-wave sleep • Clonidine for nervous system regulation • Vistaril (hydroxyzine) for calming effects and serotonin support Patient testimonials demonstrate the program's effectiveness for working professionals. David L. shared: "Super simple process. I didn't have to waste time scheduling a call or explaining my sleep struggles for the hundredth time. Sleeping again, finally." Michelle W. reported: "I've had sleep issues forever, and this is the first thing that actually helped. The whole process was smooth, no waiting rooms, no dealing with front desk people. Just got what I needed and started sleeping better almost immediately. Highly recommend!" The service operates through a dual-faceted system addressing diverse patient needs. For patients in states permitting asynchronous care, an AI-assisted platform enables personalized sleep solutions without appointment scheduling. In states requiring synchronous care, patients connect directly with licensed practitioners through virtual telehealth appointments. Currently available in over 40 states, the platform provides asynchronous care in states including Arizona, California, Colorado, Delaware, Florida, Hawaii, Idaho, Illinois, Iowa, Maine, and Michigan. States requiring virtual appointments include Connecticut, Georgia, Indiana, Kansas, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Ohio, Tennessee, Texas, and West Virginia. Emily R., a professional with demanding schedule requirements, noted: "I have a crazy work schedule and no time for doctor appointments. This was the easiest thing ever—filled out some questions, got approved, and my prescription was ready pretty fast. I don't wake up a million times a night anymore, which is honestly life-changing." Beyond prescription medications, the platform offers additional sleep health resources: • Natural supplement recommendations for patients preferring non-pharmaceutical approaches • At-home sleep testing for suspected sleep apnea cases • Physician-reviewed treatment plans • Flexible treatment adjustments and medication changes The service maintains transparent pricing with a $25 first-month trial rate, followed by standard monthly or 90-day plan options. No insurance requirements exist, and patients maintain full control over treatment continuation. Co-founded by Dr. Peter Kelly, a family medicine specialist, and Dr. David Danish, who holds dual board certification in child/adolescent and adult psychiatry, the platform combines expertise in mental health, physical health, and safe prescribing practices. Both physicians met during post baccalaureate studies at a program affiliated with Harvard, establishing a foundation for evidence-based patient care. The platform's safety protocols exclude potentially habit-forming medications while maintaining therapeutic effectiveness through carefully selected alternatives. All treatment plans receive review and approval from licensed medical practitioners. For busy professionals seeking accessible sleep disorder treatment, SleepScript MD provides comprehensive care without traditional healthcare system barriers. The platform serves patients nationwide, with ongoing expansion to additional states. To learn more about SleepScript MD's telemedicine program, call HIDDEN, or explore expert insights at https://sleepscriptmd.com/expert-mental-health-insights . ### About SleepScript MD SleepScript MD ( https://sleepscriptmd.com/about ), a subsidiary of RefillGenie Inc., and headquartered in Shelbyville, Tennessee, provides accessible, high-quality sleep healthcare through telemedicine. Co-founded by Dr. Peter Kelly (family medicine) and Dr. David Danish (dual board certified in child/adolescent and adult psychiatry), the platform combines complementary medical expertise to deliver comprehensive sleep care. The service offers both AI-assisted asynchronous care and virtual telehealth options, enabling patients to access personalized sleep solutions with safety and efficiency while maintaining the highest standards of medical oversight. Contact Details: 118 East Side Square Ste. A Shelbyville, TN 37160 United States Notes to Editors: • All clinical care is delivered by licensed physicians or nurse practitioners in accordance with state telehealth laws. • The medications discussed (Trazodone, Clonidine, Hydroxyzine) are non-controlled and selected through an evidence-based, physician-guided system. • For asynchronous eligibility, state-specific regulations apply. End of Press Release. Dr. David Danish SleepScript MD HIDDEN email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

19 Nov 2024

·www.businesswire.com

AgelessRx Enters Sleep Health Category, Underscoring Critical Role Sleep Plays in Healthspan and Lifespan

ANN ARBOR, Mich.--( BUSINESS WIRE )-- AgelessRx , a pioneer in longevity and telehealth solutions, today announced its entry into the sleep health category , building on its commitment to redefine aging and improve quality of life. With a strong emphasis on research-backed solutions, AgelessRx’s sleep program provides personalized sleep treatment plans, and two new products–prescription Trazodone and natural, over-the-counter (OTC) Tran-Q Sleep Supplement–alongside easy-to-adopt lifestyle recommendations. Guided by the latest scientific insights into sleep health, AgelessRx sleep regimens are effective, tailored to customers’ unique needs, and integrated into holistic, personalized treatment plans focused on extending lifespan and enhancing healthspan. Quality sleep is the cornerstone of cognitive and physical health, reducing the risk of chronic conditions like heart disease, diabetes, and obesity, which are linked to shorter lifespans. 1 in 3 Americans report sub-optimal sleep with the demands and distractions of modern lifestyles frequently deprioritizing rest and undermining sleep. AgelessRx’s tailored sleep solutions address this growing health crisis and are part of its ongoing mission to support the most important aspects of proactive healthcare. "Advances in research and understanding of sleep architecture underscores the importance of sleep as a major determinant of health and longevity—it’s our health insurance,” said Dr. Sajad Zalzala, co-founder and chief medical officer of AgelessRx. “The negative impacts of poor sleep outweigh any positive contributions proper diet and adequate exercise can offer. Our goal is to ensure this critical function is a core part of everyone's longevity routine.” Trazodone and Tran-Q Sleep AgelessRx’s new offerings are oral, non-habit forming interventions that support all four pillars of sleep: quantity, quality, regularity, and timing. Trazodone is a prescription medication with well-researched use as a safe, effective sleep aid and Tran-Q Sleep is a natural, melatonin-free OTC supplement designed for relaxation and sleep support. AgelessRx’s clinical team thoroughly reviews every patient’s medical history, unique needs, and health goals to determine the appropriate treatment for each individual. Together, these options serve a broad range of needs for people seeking improved sleep quality and sleep architecture—the process by which we cycle through different sleep stages. Trazodone (Rx): Studies show that Trazodone is effective at improving sleep onset and reducing nighttime awakenings and that Trazodone lowers the volume of three key neurochemical systems associated with waking: serotonin, histamine, and noradrenaline. Trazodone is recognized as a well-tolerated long-term intervention that has few side effects, boosting deep sleep without impacting rapid eye movement (REM) sleep, and minimizing next-day drowsiness. Tran-Q Sleep (OTC): Formulated with all-natural herbal ingredients, including passionflower and lavender, Tran-Q Sleep enhances the calming neurotransmitter (GABA) signaling and relaxes muscles while counter-balancing an overstimulated nervous system to gently prepare the mind and body for restful sleep. As a non-prescription option, Tran-Q Sleep caters to those seeking a natural solution for sleep improvement. For additional information about AgelessRx and its sleep products and services, please visit agelessrx.com . About AgelessRx AgelessRx is at the forefront of the longevity revolution, offering clinically validated cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials . Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram , X , and Facebook .

100 Deals associated with Trazodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00820	Trazodone Hydrochloride	N06AX05	DB00656

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	Japan	Pfizer Japan, Inc.	28 Jun 1991
Depressive Disorder	Japan	Organon & Co.	28 Jun 1991
Depressive Disorder, Major	United States	Pragma Pharmaceuticals LLC	24 Dec 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	Phase 2	Czechia	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathic pain	Phase 2	Hungary	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathic pain	Phase 2	Poland	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	16 May 2017
Diabetic peripheral neuropathy	Phase 2	China	Shenyang Funing Pharmaceutical Co Ltd.	09 May 2017
Sleep Initiation and Maintenance Disorders	Phase 2	China	Shenyang Funing Pharmaceutical Co Ltd.	19 Oct 2015
Premature Ejaculation	Phase 1	China	Shenyang Funing Pharmaceutical Co Ltd.	17 Jun 2015
Anxiety Disorders	Phase 1	China	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	10 Nov 2011
Anxiety Disorders	Phase 1	China	Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA	10 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04468776 (COZI, CTgov)	Phase 4	Sleep Initiation and Maintenance Disorders	155	Zolpidem+Trazodone (Medication (Zolpidem or Trazodone))	zfiedqyeyi(mknwwlsnkf) = dweihzzqpn whyuicwtnh (woplrnwnfe, snmncaesyp - kddglmzmfc) View more	-	24 Feb 2025
				Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I))	zfiedqyeyi(mknwwlsnkf) = odoxdsautx whyuicwtnh (woplrnwnfe, iuoycdndni - wlammhqwnw) View more
NCT04302870 (MND SMART, Pubmed)	-	Motor Neuron Disease	554	美金刚	aprhqvwbjj(xojyhuiaqx) = tjaopkabkp zaylhwppcg (aeaejtkdcv )	Negative	19 Sep 2024
				曲唑酮	aprhqvwbjj(xojyhuiaqx) = fsmtobbibe zaylhwppcg (aeaejtkdcv )
NCT03534284 (Sleep-HD, CTgov)	Phase 3	Sleep Initiation and Maintenance Disorders \| Kidney Failure, Chronic	126	Cognitive Behavioral Therapy for Insomnia (CBT-I)	kxnponifhv(zozerjmazd) = kmrqxhmcwr npxjozddox (illzzrfxjl, wuhexihkkj - yiygprkagg) View more	-	05 Feb 2024
				Trazodone (Medication- Trazodone)	kxnponifhv(zozerjmazd) = lgakdguvna npxjozddox (illzzrfxjl, trtrrindzv - hckwfmcyqd) View more
ISC2024	Not Applicable	Acute Ischemic Stroke	-	SSRI/SNRI	veuiwyiqdy(hxkmpimfai): RR = 1.29 (95% CI, 1.11 - 1.5)	-	01 Feb 2024
				Dual Antiplatelet Therapy (DAPT)
WSC2023	Not Applicable	Sleep Initiation and Maintenance Disorders	716	Lemborexant	zfllyzcirk(qtopckvgxs) = dpnzpjvpyh ktzkzhmjht (dzvnnlkxwa )	Positive	23 Oct 2023
				Trazodone	zfllyzcirk(qtopckvgxs) = bpelmwuogt ktzkzhmjht (dzvnnlkxwa )
NCT04162743 (Pubmed \| J Neurol)	Phase 4	Ischemic stroke	22	Trazodone 100 mg	rsrtashcml(msmhdlfolm) = vaskbswady tuvndphcpo (uctpxqksze ) View more	-	24 Feb 2021
				Placebo	rsrtashcml(msmhdlfolm) = ukxgfkggpu tuvndphcpo (uctpxqksze ) View more
NCT01348542 (Pubmed \| J Clin Sleep Med)	Not Applicable	Sleep Wake Disorders	15	Trazodone	wcgtnelxhb(zhrgusablc) = mhvcaaegaa eixdvcwfln (amqgqkcayj ) View more	-	15 Dec 2020
				Cognitive-Behavioral Therapy for Insomnia (CBT-I)	wcgtnelxhb(zhrgusablc) = yhsyrhnuty eixdvcwfln (amqgqkcayj ) View more
NCT03202979 (Pubmed \| CNS Drugs)	Phase 2	Diabetic Neuropathies	142	TRZ30	kohrzhsbsy(jnyydcwayy) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders ohkalophla (ilkhwrloht )	-	01 Nov 2020
				TRZ60
NCT03516630 (Pubmed \| J Clin Pharmacol)	Phase 1	-	20	Trazodone 20 mg	fhiausboui(lsqplbgzdm) = fqtcddlvoi qdzfwonspu (xkzvlytatq )	-	02 Jun 2020
				Trazodone 60 mg	fhiausboui(lsqplbgzdm) = leozvppsci qdzfwonspu (xkzvlytatq )
NCT02458469 (REST-SCI, CTgov)	Phase 2	Spinal Cord Injuries \| Sleep Apnea, Central	15	buspirone (Buspirone)	ulurnirxle(wrzlkudxyf) = zohunktgle omzeknmnro (xulhuvsxdc, 0.9) View more	-	09 Apr 2020
				Trazodone (Trazodone)	ulurnirxle(wrzlkudxyf) = vtwlxwjycg omzeknmnro (xulhuvsxdc, 1.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis